Streetbeat News

Regulatory

TKUNF

Greece has made medical marijuana available in pharmacies, seven years after its legalization, for patients with specific conditions such as chemo-induced nausea and chronic pain. The first legal patient, Anna Paga, reported significant pain relief from using medical cannabis. The country has also seen the establishment of its first medical cannabis production plant by Tikun-Olam Cannbit's subsidiary, Tikun Europe. This move is part of broader efforts to regulate medical marijuana use and curb the illegal market.

Portfolio Pulse from Nina Zdinjak

February 26, 2024 | 2:20 pm

JNJ

Johnson & Johnson announced the expansion of the IMBRUVICA label in the US to include an oral suspension formulation for adult patients in its approved indications. This development could potentially enhance the accessibility and ease of administration for patients requiring IMBRUVICA treatment.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:19 pm

EWT

FXI

SPY

China's Commerce Ministry reported that Minister Wang voiced serious concerns to the U.S. regarding tariffs and Taiwan-related issues in the economic and trade sectors, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:12 pm

SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced positive results from a Phase 2 study of neffy, an investigational epinephrine nasal spray, for treating chronic spontaneous urticaria, a skin disorder. The study met its primary endpoints, showing significant improvement in symptoms as early as 5 minutes after dosing. The data supports further development of neffy, with an outpatient study for acute flares planned for 2024 and a pivotal study potentially starting in 2025.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:03 pm

RVSN

Rail Vision Ltd. (NASDAQ:RVSN) has received regulatory approval and certification for its Main Line system in the European Union, setting new safety standards for railway operations. This approval marks a significant milestone, allowing for the expansion and adoption of Rail Vision's technology across Europe, aiming to enhance railway safety and operational efficiency.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:52 pm

AKLI

Akili, Inc. (NASDAQ:AKLI) and its Japanese partner Shionogi & Co. Ltd announced the submission of the digital therapeutic SDT-001, a localized version of Akili's EndeavorRx for pediatric ADHD, for marketing approval in Japan. The submission follows favorable results from a Phase 3 clinical trial demonstrating significant improvements in ADHD symptoms among pediatric patients. No safety concerns were observed. Approval in Japan could expand access to an effective ADHD treatment option in a market with limited pharmaceutical options for pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:49 pm

ABBV

ALVO

TEVA

Teva Pharmaceuticals and Alvotech announced FDA approval for Simlandi, an interchangeable biosimilar to AbbVie's Humira, for various conditions. Simlandi, exclusively commercialized by Teva in the U.S., is the first high-concentration, citrate-free biosimilar to Humira with interchangeability status. This allows pharmacy-level substitution without prescriber consultation. Teva and Alvotech's strategic partnership, initiated in 2020, was recently extended. Additionally, Teva formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing of Austedo. Following the news, TEVA and ALVO stocks saw significant premarket gains.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 1:49 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

ENLV

Enlivex has been granted regulatory authorization by Israel's Health Ministry to begin a Phase 1/2 trial for Allocetra in treating knee osteoarthritis. This marks a significant step forward in the development of Allocetra, potentially impacting its future market positioning and investor interest in ENLV.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:36 pm

SPY

USA Building Permits for the month were reported at 1.489M, slightly above the estimated 1.470M but below the previous month's 1.493M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm